Innogen Pharmaceuticals Licenses Efsubaglutide Alfa to Arcera Life Sciences for Strategic Global Market Expansion
Innogen Pharmaceuticals has entered a licensing agreement with Arcera Life Sciences, granting exclusive rights to Efsubaglutide Alfa in select countries across Africa, Latin America, the Middle East, and Eastern Europe. The deal includes upfront and milestone payments totaling $38 million, with potential value exceedi…